De Placido S - Search Results

1

Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues.

Conforti A, Schettini F, Vallone R, Di Rella F, De Rosa P, De Santo I, Giuliano M, Arpino G, Lauria R, De Placido S, Caputo R, De Laurentiis M, Nazzaro G, De Placido G, Locci M, Alviggi C. Conforti A, et al. Among authors: de placido g, de placido s, de rosa p, de santo i, de laurentiis m. Breast J. 2019 Nov;25(6):1310-1311. doi: 10.1111/tbj.13474. Epub 2019 Jul 23. Breast J. 2019. PMID: 31338934 No abstract available.

2

Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.

De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, Pagliarulo C, Panico L, Pettinato G, Petrella G, Bianco AR. De Placido S, et al. Among authors: de laurentiis m. Clin Cancer Res. 2003 Mar;9(3):1039-46. Clin Cancer Res. 2003. PMID: 12631604 Clinical Trial.

3

Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease.

Di Lorenzo G, Autorino R, De Laurentiis M, Bianco R, Lauria R, Giordano A, De Sio M, D'Armiento M, Bianco AR, De Placido S. Di Lorenzo G, et al. Among authors: de placido s, de sio m, de laurentiis m. Tumori. 2003 Jul-Aug;89(4):349-60. doi: 10.1177/030089160308900402. Tumori. 2003. PMID: 14606635 Review.

4

FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.

Di Lorenzo G, Autorino R, Giordano A, Giuliano M, D'Armiento M, Bianco AR, De Placido S. Di Lorenzo G, et al. Among authors: de placido s. Jpn J Clin Oncol. 2004 Dec;34(12):747-50. doi: 10.1093/jjco/hyh132. Jpn J Clin Oncol. 2004. PMID: 15640506

5

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S. De Laurentiis M, et al. Among authors: de placido s. Clin Cancer Res. 2005 Jul 1;11(13):4741-8. doi: 10.1158/1078-0432.CCR-04-2569. Clin Cancer Res. 2005. PMID: 16000569 Free article.

6

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Arpino G, et al. Among authors: de placido s. J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. doi: 10.1093/jnci/dji249. J Natl Cancer Inst. 2005. PMID: 16145046

7

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R. Arpino G, et al. Among authors: de placido s. J Natl Cancer Inst. 2007 May 2;99(9):694-705. doi: 10.1093/jnci/djk151. J Natl Cancer Inst. 2007. PMID: 17470737

8

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.

Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G, Pacilio C, Piccirillo MC, Rossi E, D'Aiuto G, Thomas R, Gori S, Colozza M, De Placido S, Lauria R, Signoriello G, Gallo C, Perrone F, de Matteis A. Nuzzo F, et al. Among authors: de placido s, de matteis a, de maio e. Crit Rev Oncol Hematol. 2008 May;66(2):171-80. doi: 10.1016/j.critrevonc.2007.10.006. Epub 2007 Dec 21. Crit Rev Oncol Hematol. 2008. PMID: 18160303 Clinical Trial.

9

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S. De Laurentiis M, et al. Among authors: de placido s. J Clin Oncol. 2008 Jan 1;26(1):44-53. doi: 10.1200/JCO.2007.11.3787. J Clin Oncol. 2008. PMID: 18165639

10

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.

Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, Imbimbo C, Perdonà S, Giordano A, Giuliano M, Labianca R, De Placido S. Di Lorenzo G, et al. Among authors: de placido s. Eur Urol. 2008 Nov;54(5):1089-94. doi: 10.1016/j.eururo.2008.01.082. Epub 2008 Feb 5. Eur Urol. 2008. PMID: 18276061 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

394 results

Search Page